Human medicines European public assessment report (EPAR): Sorafenib Accord, sorafenib, Date of authorisation: 09/11/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 5, Status: Authorised

Ethical use of animals in medicine testing

Transparency: exceptional measures for COVID-19 medicines

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 55, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised

Human medicines European public assessment report (EPAR): Jardiance, empagliflozin, Date of authorisation: 22/05/2014, Revision: 32, Status: Authorised

Orphan designation: Humanised IgG1 monoclonal antibody against human epidermal growth factor receptor 2 Treatment of gastric cancer, 22/05/2025 Positive

Human medicines European public assessment report (EPAR): BroPair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Date of authorisation: 03/10/2011, Revision: 20, Status: Authorised